Benzodiazepines and Z-Drug Use among HIV-Infected Patients in Taiwan: A 13-Year Nationwide Cohort Study
Table 2
Predictors of use of BZDs and Z-drugs among HIV-infected patients and the controls.
Characteristics
Any use of BZDs and Z-drugs*
Long-term use of BZDs and Z-drugs*,#
OR (95% CI)
value
OR (95% CI)
value
HIV, presence versus absence
8.70 (6.82~10.97)
<0.001
5.06 (3.63~7.04)
<0.001
Psychiatric comorbidities, presence versus absence
Any mood disorder
9.86 (5.37~18.12)
<0.001
15.69 (10.18~24.17)
<0.001
Any anxiety disorder
7.24 (3.57~14.67)
<0.001
6.53 (4.34~9.82)
<0.001
Alcohol use disorder
3.21 (0.72~14.43)
0.128
1.55 (0.29~8.38)
0.621
Substance use disorder
1.26 (0.83~1.92)
0.281
2.33 (1.49~3.64)
<0.001
Insomnia
20.09 (10.49~38.47)
<0.001
10.69 (7.46~15.31)
<0.001
Adjusted for demographic data and psychiatric comorbidities and HIV as a binary variable.
#Long-term use of BZDs and Z-drugs means cumulative defined daily dose ≧180. OR: odds ratio; CI: confidence interval. Bold type indicates the statistical significance.
